Navigation Links
Bruin Biometrics, LLC Conducts Clinical Trials to Detect Pressure Ulcers with the SEM Scanner
Date:11/21/2013

LOS ANGELES, Nov. 21, 2013 /PRNewswire/ -- Bruin Biometrics, LLC ("BBI") today announced results from two IRB-approved clinical trials conducted with the SEM Scanner, a Class IIA medical device that is intended to detect localized tissue edema and pressure induced tissue damage which may lead to the formation of pressure ulcers.

BBI enrolled thirty-one healthy subjects in a pilot study conducted in Los Angeles, California to assess the reliability of the SEM Scanner. Results indicate that the SEM Scanner gives consistent readings and is reliable across different users and across different device models.

BBI also sponsored an investigational, non-significant risk study to collect data needed to analyze SEM Scanner readings at the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts. Fifty subjects from the adult Critical Care Unit were enrolled in the trial and followed for five days. Although the medical center reports annual pressure ulcer incidence of 5.08%, zero subjects developed a pressure ulcer during the course of the BBI trial. Analysis of trial data is underway, and a final study report is expected in early 2014.

BBI will sponsor additional trials throughout 2014. The first will take place in the United States and will evaluate SEM Scanner readings in subjects with known pressure ulcers. A second study will enroll subjects throughout the United States and Europe in order to evaluate the SEM Scanner's effectiveness in lowering the incidence of pressure ulcers against the current standard of care.

About the SEM Scanner:

The SEM Scanner is a point of care diagnostic device that measures increased fluid content within the underlying tissue of skin known as subepidermal moisture (SEM). In clinical studies, SEM has been shown to identify pressure-induced tissue damage — including pressure ulcers — up to 10 days before damage is visible on the skin's surface. BBI developed the SEM Scanner in conjunction with research colleagues at the University of California at Los Angeles (UCLA), notably Barbara Bates-Jensen, PhD, RN, CWOCN, FAAN.

The SEM Scanner is not yet available for sale in the United States. For additional information, please visit www.bruinbiometrics.com.


'/>"/>
SOURCE Bruin Biometrics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bruin Biometrics, LLC Announces New Board Members
2. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
3. Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
4. PRA Named "Clinical Company of the Year" in National Contest for Second Year
5. Teledyne DALSA Expands Dynamic Flat Detector Series to Benefit Clinical Procedures
6. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
7. Non-Randomized, Multi-Center US Clinical Trial of the GORE ACUSEAL Vascular Graft Presented at VEITHsymposium in New York
8. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
9. Irvine Center for Clinical Research Announces Open Enrollment for New Low Testosterone Study
10. Xcelience hires Clinical Supplies VP; Opens Birmingham, UK Site
11. Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve ... his tenure, Paul has served us in multiple leadership roles ... Pharmacy in Jun. 2015 and has provided decisive, strategic leadership ...
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
(Date:8/4/2017)... 2017  Agragen, LLC, a Cincinnati ... biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces a ... drug candidates, AGR131.  This drug is designed to ... blood of patients suffering from inflammatory conditions such ... Biological pharmaceuticals ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... for Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding ... of Health and Human Services. , This funding marks, the fourth time the ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the leading provider of ... world, is excited to announce Andrew Ly as the winner of the LabRoots Summer ... costs. , Ly, who is in his third year at the University of ...
(Date:8/16/2017)... ... , ... With a new PD diagnosis every nine minutes, research is critical ... are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board ... in all areas relevant to PD research. The SAB meets annually to review ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
Breaking Medicine News(10 mins):